SCHEMBL6701422

SCHEMBL6701422

O=C1C=C(c2ccccc2)C(C(=O)NCc2ccccc2)O1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.46
ALDH1A1 P00352 2/20 0.46
USP2 O75604 1/20 0.46
MC4R P32245 1/20 0.46
HTT P42858 1/20 0.45
LMNA P02545 3/20 0.45
CHRNB2 P17787 1/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA4 P43681 1/20 0.44
TSHR P16473 2/20 0.43
PTGES O14684 1/20 0.43
HSD17B10 Q99714 1/20 0.43
HPGDS O60760 1/20 0.43
KMT2A Q03164 1/20 0.41
CACNA1G O43497 1/20 0.41
HTR1A P08908 1/20 0.41
HTR1B P28222 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6705567 0.97 ALDH1A1 (0.47) HPGDALDH1A1USP2MC4RHTT
SCHEMBL6704676 0.91 TP53 (0.46) ALDH1A1LMNAPTGESHSD17B10CACNA1G
SCHEMBL6701163 0.76 LMNA (0.40) LMNAKMT2ASMN1; SMN2
SCHEMBL6699001 0.75 LMNA (0.46) HPGDALDH1A1HTTLMNATSHR
SCHEMBL5428707 0.71 HPGD (0.48) HPGDALDH1A1USP2MC4RHTT
SCHEMBL29221193 0.67 APEX1 (0.44) HPGDHTTLMNATSHRKMT2A
SCHEMBL29941835 0.66 HPGD (0.66) HPGDALDH1A1USP2MC4RHTT
SCHEMBL8998862 0.66 HPGD (0.66) HPGDALDH1A1USP2MC4RHTT
SCHEMBL16446870 0.66 HPGD (0.57) HPGDALDH1A1USP2MC4RHTT
SCHEMBL16446872 0.66 HPGD (0.57) HPGDALDH1A1USP2MC4RHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040102488-A1 Butenolide and pentenolide derivatives as kinase inhibitors MORPHOCHEM AG (DE) 2004-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102488-A1 Butenolide and pentenolide derivatives as kinase inhibitors MAP3K20, MAP3K21, MAP3K1 HPGD 981/4885ALDH1A1 2905/4885USP2 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.